Format

Send to

Choose Destination
Cell Regen (Lond). 2018 Nov 2;7(2):40-44. doi: 10.1016/j.cr.2018.09.002. eCollection 2018 Dec.

Approaches for generation of anti-leukemia specific T cells.

Jin Z1,2, Xu L1,3, Li Y1,3.

Author information

1
Key Laboratory for Regenerative Medicine of Ministry of Education; Institute of Hematology, School of Medicine; Jinan University, Guangzhou, 510632, China.
2
Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou, 510632, China.
3
Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.

Abstract

As three decades ago, it was reported that adoptive T cell immunotherapy by infusion of autologous tumor infiltrating lymphocytes (TILs) mediated objective cancer regression in patients with metastatic melanoma. A new era of T cell immunotherapy arose since the improvement and clinical use of anti-CD19 chimeric antigen receptor T cells (CAR-T) for the treatment of refractory and relapsed B lymphocyte leukemia. However, several challenges and difficulties remain on the way to reach generic and effective T cell immunotherapy, including lacking a generic method for generating anti-leukemia-specific T cells from every patient. Here, we summarize the current methods of generating anti-leukemia-specific T cells, and the promising approaches in the future.

KEYWORDS:

ACT, adoptive cellular immunotherapy; APL, promyelocytic leukemia; Anti-leukemia T cell; B-ALL, cell acute lymphoblastic leukemia; CAR-T; CAR-T, chimeric antigen receptor T cells; CML, chronic myelogenous leukemia; CR, complete remission; CTLs, cytotoxic T cells; DLI, donor lymphocyte infusion; FLT3-ITD, FLT3 internal tandem duplication; GVHD, graft-versus-host disease; GVL, graft-versus-leukemia; HLA, human leukocyte antigen; HPCs, hematopoietic progenitor cells; IL-2, interleukin-2; Ig, immunoglobulin; T cell immunotherapy; T cell reprogramming; TAA, tumor-associated antigen; TCR-T; TCR-T, TCR gene-modified T cell; TIL, infiltrating lymphocytes; TKI, tyrosine kinase inhibitor; WT1, Wilm's tumor antigen 1; allo-HSCT, allogeneic hematopoietic stem cell transplantation; hESC, human embryonic stem cell; iPSCs, induced pluripotent stem cells; iTs, induced functional T cells; scFv, single-chain variable fragment

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center